斑马鱼模型在新精神活性物质代谢研究中的应用
Application of zebrafish model in the metabolism of new psychoactive substances
-
摘要: 斑马鱼具有体型小、易于饲养、繁殖成本低、繁殖率高等诸多优势,是药物代谢研究的新型模式生物。本文概述斑马鱼代谢模型的构建,介绍斑马鱼模型的基因与人类高度相似性以及其发达的酶系统、较低的基质效应等优点;总结斑马鱼模型在合成大麻素类、芬太尼类、哌嗪类、合成卡西酮类等各类新精神活性物质研究中的应用;综述斑马鱼中体内常见的代谢反应包括Ⅰ相(氧化、N-脱甲基、O-脱乙基化、羟化和N-脱烷基)和Ⅱ相(硫酸化和葡萄糖醛酸化)反应,说明其代谢物种类与真实人体体液样本之间的差异主要和酶的种类有关,指出斑马鱼模型在研究新精神活性物质方面的巨大潜力和进一步研究趋势。Abstract: Zebrafish is a novel model organism for drug metabolism research because of its small size, easy feeding, low reproduction cost and high reproduction rate.This paper outlines the construction of zebrafish metabolic model, illustrating the advantages of zebrafish model with high genetic similarity to human, well-developed enzyme system, and low substrate effect; and then reviews the application of zebrafish model in the synthesis of various new psychoactive substances such as cannabinoids, fentanyl, piperazines, and synthetic cathinones.The common metabolic reactions in zebrafish, including phase I (oxidation, N-demethylation, O-deethylation, hydroxylation and N-desalkylation) and phase II (sulfation and glucuronidation) reactions, are summarized, and the differences between the metabolites of zebrafish and those of real human body fluid samples are mainly related to the types of enzymes.This paper also points out the great potential and further research trends of zebrafish model in the study of new psychoactive substances.
-
Keywords:
- zebrafish model /
- new psychoactive substance /
- metabolite /
- application
-
《
学报》是由教育部主管、中国药科大学主办的国家级药学学术刊物,被国内外重要检索数据库收录,为中国中文核心期刊、中国科学引文数据库(CSCD)核心期刊、中国精品科技期刊及中国高校百佳科技期刊。主要报道药学学科创新性科研成果,登载合成药物化学 、天然药物化学、中药学、药剂学、药物分析学、药物代谢动力学、生物技术、生物制药工程、药理学及其他相关学科的研究成果和学术动态。本刊为双月刊,128页,国内外公开发行。1. 稿件受理和注意事项
1.1 本刊设药学前沿、获奖成果、论文、专家评述、综述、专论等栏目。论文一般在6000~8000字,综述 一 般不超过8000字,引用文献中近 5 年发表的应占 70% 以上,应包含本课题组相关研究及思考,并在文末附注已发表的相关科研成果。
1.2 作者可以通过登录我刊网站的稿件处理系统上传稿件(http://manuscripts.cpu.edu.cn),来稿须附投稿介绍信(本刊网站下载模板),来稿请勿一稿多投(以研究快讯发表或在学术会议上宣读过的论文,可在充实内容后以研究论文发表),文责自负。本刊稿件免收审理费。
1.3 来稿须注明通信作者,用上标 “*”标注在作者署名后,并在首页脚注处注明其电话、传真和E-mail。基金资助论文请提供相关证明的复印件(扫描后上传至稿件处理系统),并在首页脚注注明基金名称和项目编号,在英文关键词后注明基金名称(英文)和项目编号。例:
*通信作者 Tel:025-83271566 E-mail:xuebao@cpu.edu.cn
基金项目 国家自然科学基金项目(No.59637050)
This study was supported by the National Natural Science Foundation of China(No.59637050)
1.4 来稿进入审稿程序后,一般 2 个月内通知作者稿件审理情况。投稿后 2 个月未收到通知者,请直接与编辑部联系。基金资助论文在符合发表的条件下优先录用,国家重大项目基金论文可进入快速评审通道,并尽快发表。
1.5 需作修改的稿件,请作者按照退修通知要求修改并逐项加以说明。请将修改稿连同修改说明上传至本刊稿件处理系统。退修时间超过60 天,则按新稿处理。
1.6 来稿是否采用,均由本刊编委会最终审定。本编辑部对来稿可作文字上的修改、删节,涉及内容的重大修改须征得作者同意。文稿刊用前,编辑部与作者签署版权转让合同。为扩大学术交流渠道,本刊被国内外著名数据库收录。稿件一经录用,将同时被数据库收录,作者著作权使用费与本刊稿酬一次性给付。如作者不同意收录,请在投稿时声明,否则将视为同意。
2. 文稿要求
2.1 文题 文题应简明、具体,确切反映文章的主旨。 中文题名一般不超过20 个字,应避免使用非公知公用的缩略语、字符、代号和商品名称,尽可能不出现数学式和化学式。英文题名应与中文题名含义一致。
2.2 作者 署名仅限在选定课题、制定研究方案、具体研究工作和撰写文稿等方面作出主要贡献,并能就论文内容进行答辩者,一般不超过6人。为本文提供帮助的其他人可写在致谢项下。请标明作者的工作单位,包括单位全称、所在城市及邮政编码。
2.3 摘要 论文需要同时提供中文和英文摘要。摘要以提供论文的内容梗概为目的,不加评论和补充解释。简明、确切地论述研究目的、采用的方法原理和结论,具有相对独立性。中文和英文摘要均要求采用报道性摘要。具体要求:中英文摘要均为一段式,内容比较具体,一般需要列举关键数据。中英文摘要应保持内容基本一致。
2.4 关键词 一般3~8个,多个关键词之间用分号分隔,中英文关键词应相对应。
2.5 引言 概述课题的理论依据、研究思路、实验基础及国内外研究现状,明确指出本文的研究目的及创新之处。
2.6 材料 动植物、微生物应注明拉丁学名、植物标本应注明鉴定人和存放地。实验动物应注明清洁等级和合格证号。当实验以人或动物为研究对象时,作者应当声明,只有符合机构责任委员会的伦理(道德)标准或依照1975年制定的《赫尔辛基宣言》(1983 年修订),才能进行人体实验。其他主要材料、仪器应说明品种、来源、规格、型号、产地。
2.7 方法 尽量简单明了,便于他人重复实验。一般方法可引文献,如有改进的地方应重点突出,创新的方法则宜详述。
2.8 结果和讨论 重点叙述本文研究的结果,新发现及得出的结论与观点。讨论中不重复引言和结果中已叙述的内容。
2.9 图表 能用文字说明的问题,尽量不用图表。同一数据不要同时用图和表表示。图表一律用英文表达。表采用“三线表”。图中坐标的量和单位符号标于坐标轴外侧。照片要求清晰。
2.10 结构式和反应式 结构式不要夹杂于行文中,而应以相应的化学名称或分子式表示。反应式转行时应在反应方向符号“→、$ \rightleftharpoons $”等处转行。请尽量采用ChemDraw软件绘制结构式。
2.11 数字 凡是可以用阿拉伯数字且使用得体的地方,均应使用阿拉伯数字,并应注意有效数字的使用。平均数应写出标准差($ \bar{x}\pm s $)。百分数范围 20%~30%不能写成 20~30%。统计学显著性用 “*P < 0.05,**P < 0.01,***P < 0.001 vs A”表示。
2.12 单位和量 严格执行GB 3100-3102有关量和单位的规定。量的符号一律采用斜体,如:相对分子质量(Mr),吸收度(A),质量浓度(c),时间(t),等。量值的单位,一律使用国际符号,并用正体,如:1 M HCl应为1 mol/L HCl,转速rpm 应为r/min。量值和单位间空格。图表中用符号表示数值的量和单位时,采用量与单位相比的形式,如 t/min, c/(mol/L)。在一个组合剂量单位代号内,不得有一条以上的斜线,如mg/kg/d应写成mg/(kg·d)。
2.13 代号和缩写 文中可使用国际代号和缩写,例如:1秒:1 s;2分钟:2 min;3小时:3 h;4天:4 d。相对标准偏差RSD,静脉注射iv,肌肉注射im,腹腔注射ip,皮下注射sc,灌胃ig,口服po。
2.14 药名 中文药名以《中华人民共和国药典》(2020年版)和《中国药品通用名称》(化学工业出版社, 2014)为准。英文药名尽量与国际通用名称一致,采用国际非专利药名(international nonproprietary names, INN)。国家食品药品监督管理局批准的新药,用批准的药名。药名较长时可缩写,但首次出现时应予以注明。药名应少用代号,不用商品名。
2.15 理化数据表示法 请参照以下写法:······得白色结晶(1.8 g, 76.0%):mp 209~211℃(EtOH/Et2O); $ [{\text{α}}]^{20}_{\rm{D}} $−141.30°(c 0. 403, CHCl3 ):Anal. C21H25O2Cl, C 72. 51, H 7.31, Cl 10. 32(Req. C 72. 89, H 7.31, Cl 10. 29);TLC Rf 0. 44(CHCl3-EtOH, 9∶1);UV(CH3OH)λmax 284(lg ε 4.42)nm;IR( KBr, ν): 3370, 3000, 2200, 1600 cm−1 ;1 H NMR (CDCl3, 300 MHz)δ:0.94, 1.16(6H, s, C18 和 C19-CH3 ), 5.59 (1H, s, C6-H), 6.16(2H, s, C4-H, C7-H);MS m/z 343(M)+ 。
2.16 参考文献 参考文献应限于作者直接阅读过的、发表在正式出版物上的文献。采用顺序编码制,在文内按论文引用文献出现的先后用阿拉伯数字连续编号,如[1-2][3-5],标在相应文字的右上角。
为利于计算机处理和保证数据库准确检索与统计的原则,须用文献类型标识标注参考文献的类型。 电子文献被引用时需在参考文献类型标识中同时标明其载体类型[文献类型标识/载体类型标识],如网上期刊(J/OL)。
常见参考文献类型及其标识:
文献类型 专著 论文集 报纸文章 期刊文章 标识 M C N J 文献类型 学位论文 报告 标准 专利 标识 D E S P 参考文献的著录格式示例:
连续出版物中的析出文献
作者只列3人,后面加“et al”,姓名采用姓前名后著录法,西文刊名缩写按 Index Medicus,不要缩写点,中文刊名用英文缩写名称,括号内加注中文期刊的刊名。
[序号] 作者. 题名[J]. 刊名, 年, 卷(期): 起止页码.
[1] Zhang JY, Zhang JS, Zhang Y, et al. Studies on the intes-tinal absorption of crocin in rats and determination of the partition coefficient[J]. J China Pharm Univ(中国药科大学学报), 2004, 35(3): 283-284.
[2] Zhang HH, Kumar S, Barnett AH, et al. C eiling culture of mature human adipocytes:use in studies of adipocyte functions[J]. J Endocrinol, 2000, 164(1/2): 119-128.
专 著
[序号] 编者. 书名[M]. 版本(第 1 版不写). 出版地: 出版者, 出版年: 起止页码.
[3] Qi RM, Wang ZG, Wang SQ. Advances in Pharmacology (药理学进展)[M]. Beijing: People’s Medical Publish-ing House, 2003: 74.
[4] Peebles PZ, Jr. Probability, Random Rariable, and Ran-dom Signal Principles[M]. 4th ed. New York: McGraw Hill, 2001: 149.
标 准
[序号] 起草责任著. 标准代号 标准序号—发布年 标准名称[S]. 出版地: 出版者, 出版年: 引文页码.
[5] China Association for Standardization. GB/T 21853−2008 Chemicals−Partition Coeficient ( n-octanol/water)−Shake Flask Method [化学品分配系数(正丁醇-水)摇瓶法试验][S]. Beijing: Standards Press of China, 2008.
[6] Chinese Pharmacopoeia Commission. Chinese Pharmaco-poeia: part 2( 中华人民共和国药典:二部)[S]. Bei-jing: China Medical Science Press, 2010: 310-312 .
专利文献
[序号] 专利申请者或所有者.专利题名: 专利号[ P]. 公 告日期或公开日期[引用日期].
[7] Lafon L. New benzhydrysulphinyl derivatives: 4066686A[P]. 1978-01-03[2011-10-25].
电子文献
[序号] 主要责任者. 题名:其他题名信息[文献类型标识/载体类型标识]. 出版地: 出版者,出版年(更新或修改日期)[引用日期]. 获取和访问路径.
[8] U. S. Food and Drug Administration. FDA approves shard system REMS for TIRF products[EB/OL].(2011-12-29)[2012-01-13]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285345.htm.
学位论文
[序号] 作者.题名[D]. 保存地: 保存单位, 年份.
[9] Tian Z. Study of the clinical anti-aggregating effect of picotamide on platelet(吡考他胺抗血小板聚集性的临床研究)[D]. Changchun: Jilin University, 2004.
(2024年2月修订)
-
[1] . https://www.unodc.org/LSS/Page/NPS .[2] Brandt SD,King LA,Evans-Brown M. The new drug phenomenon[J]. Drug Test Anal,2014,6(7/8):587-597. [3] Wagmann L,Maurer HH. Bioanalytical methods for new psychoactive substances[J]. Handb Exp Pharmacol,2018,252:413-439. [4] Meyer MR. New psychoactive substances:an overview on recent publications on their toxicodynamics and toxicokinetics[J]. Arch Toxicol,2016,90(10):2421-2444. [5] Meyer MR. Toxicokinetics of NPS:Update 2017[M]. City:Handb Exp Pharmacol,2018. [6] Diao XX,Huestis MA. New synthetic cannabinoids metabolism and strategies to best identify optimal marker metabolites[J]. Front Chem,2019,7:109. [7] Streisinger G,Walker C,Dower N,et al. Production of clones of homozygous diploid zebra fish (Brachydanio rerio)[J]. Nature,1981,291(5813):293-296. [8] Carten JD,Bradford MK,Farber SA. Visualizing digestive organ morphology and function using differential fatty acid metabolism in live zebrafish[J]. Dev Biol,2011,360(2):276-285. [9] Ho SY,Pack M,Farber SA. Analysis of small molecule metabolism in zebrafish[J]. Methods Enzymol,2003,364:408-426. [10] Thompson ED,Burwinkel KE,Chava AK,et al. Activity of Phase I and Phase II enzymes of the benzo[a]pyrene transformation pathway in zebrafish (Danio rerio) following waterborne exposure to arsenite[J]. Comp Biochem Physiol C Toxicol Pharmacol,2010,152(3):371-378. [11] Zhang Q,Ji CY,Yan L,et al. The identification of the metabolites of chlorothalonil in zebrafish (Danio rerio) and their embryo toxicity and endocrine effects at environmentally relevant levels[J]. Environ Pollut,2016,218:8-15. [12] Weigt S,Huebler N,Strecker R,et al. Zebrafish (Danio rerio) embryos as a model for testing proteratogens[J]. Toxicology,2011,281(1/2/3):25-36. [13] Fleming A,Sato M,Goldsmith P. High-throughput in vivo screening for bone anabolic compounds with zebrafish[J]. J Biomol Screen,2005,10(8):823-831. [14] Kithcart A,MacRae CA. Using zebrafish for high-throughput screening of novel cardiovascular drugs[J]. JACC Basic Transl Sci,2017,2(1):1-12. [15] Brugman S. The zebrafish as a model to study intestinal inflammation[J]. Dev Comp Immunol,2016,64:82-92. [16] Capiotti KM,Antonioli R Junior ,Kist LW,et al. Persistent impaired glucose metabolism in a zebrafish hyperglycemia model[J]. Comp Biochem Physiol B Biochem Mol Biol,2014,171:58-65.[17] Pinho BR,Reis SD,Guedes-Dias P,et al. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model:therapeutic implications for Parkinson''s disease[J]. Pharmacol Res,2016,103:328-339. [18] Shams S,Rihel J,Ortiz JG,et al. The zebrafish as a promising tool for modeling human brain disorders:a review based upon an IBNS symposium[J]. Neurosci Biobehav Rev,2018,85:176-190. [19] Hu BX,Dong X,Fan HW,et al. Cardiotoxicity evaluation of three novel proteasome inhibitors in zebrafish[J]. J China Pharm Univ(中国药科大学学报),2019,50(4):452-458. [20] Wan YL,Zhong H,Chen L,et al. Synthesis,anti-melanoma activity and acute toxicity of aporphine alkaloids in zebrafish[J]. J China Pharm Univ(中国药科大学学报),2021,52(5):529-535. [21] de Souza Anselmo C,Sardela VF,Matias BF,et al. Is zebrafish (Danio rerio) a tool for human-like metabolism study[J]? Drug Test Anal,2017,9(11/12):1685-1694. [22] Sneddon LU,Halsey LG,Bury NR. Considering aspects of the 3Rs principles within experimental animal biology[J]. J Exp Biol,2017,220( Pt 17 ):3007-3016.[23] Brox S,Seiwert B,Haase N,et al. Metabolism of clofibric acid in zebrafish embryos (Danio rerio) as determined by liquid chromatography-high resolution-mass spectrometry[J]. Comp Biochem Physiol C Toxicol Pharmacol,2016,185/186:20-28. [24] Shen WW,Wei YJ,Tang DQ,et al. Metabolite profiles of ginsenosides Rk1 and Rg5 in zebrafish using ultraperformance liquid chromatography/quadrupole-time-of-flight MS[J]. J Ginseng Res,2017,41(1):78-84. [25] Jones HS,Trollope HT,Hutchinson TH,et al. Metabolism of ibuprofen in zebrafish larvae[J]. Xenobiotica,2012,42(11):1069-1075. [26] Wang GW,Chen HY,Du ZK,et al. In vivo metabolism of organophosphate flame retardants and distribution of their main metabolites in adult zebrafish[J]. Sci Total Environ,2017,590/591:50-59. [27] Alderton W,Berghmans S,Butler P,et al. Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae[J]. Xenobiotica,2010,40(8):547-557. [28] Chng HT,Ho HK,Yap CW,et al. An investigation of the bioactivation potential and metabolism profile of zebrafish versus human[J]. J Biomol Screen,2012,17(7):974-986. [29] Richter LHJ,Herrmann J,Andreas A,et al. Tools for studying the metabolism of new psychoactive substances for toxicological screening purposes — A comparative study using pooled human liver S9,HepaRG cells,and zebrafish larvae[J]. Toxicol Lett,2019,305:73-80. [30] Park YM,Meyer MR,Müller R,et al. Drug administration routes impact the metabolism of a synthetic cannabinoid in the zebrafish larvae model[J]. Molecules,2020,25(19):4474. [31] Diekmann H,Hill A. ADMETox in zebrafish[J]. Drug Discov Today Dis Models,2013,10(1):e31-e35. [32] Howe K,Clark MD,Torroja CF,et al. The zebrafish reference genome sequence and its relationship to the human genome[J]. Nature,2013,496(7446):498-503. [33] Goldstone JV,McArthur AG,Kubota A,et al. Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish[J]. BMC Genomics,2010,11:643. [34] Xu CJ,Li CYT,Kong ANT. Induction of phase I,II and III drug metabolism/transport by xenobiotics[J]. Arch Pharm Res,2005,28(3):249-268. [35] Tseng HP,Hseu TH,Buhler DR,et al. Constitutive and xenobiotics-induced expression of a novel CYP3A gene from zebrafish larva[J]. Toxicol Appl Pharmacol,2005,205(3):247-258. [36] Almazroo OA,Miah MK,Venkataramanan R. Drug metabolism in the liver[J]. Clin Liver Dis,2017,21(1):1-20. [37] Huang HY,Wu Q. Cloning and comparative analyses of the zebrafish Ugt repertoire reveal its evolutionary diversity[J]. PLoS One,2010,5(2): e9144 .[38] Christen V,Fent K. Tissue-,sex- and development-specific transcription profiles of eight UDP-glucuronosyltransferase genes in zebrafish (Danio rerio) and their regulation by activator of aryl hydrocarbon receptor[J]. Aquat Toxicol,2014,150:93-102. [39] Jang M,Yang W,Shin I,et al. Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse[J]. Int J Legal Med,2014,128(2):285-294. [40] De Brabanter N,Esposito S,Geldof L,et al. In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)[J]. Forensic Toxicol,2013,31(2):212-222. [41] Nadja W,Frederike N,Doerr AA,et al. Comparison of in vitro and in vivo models for the elucidation of metabolic patterns of 7-azaindole-derived synthetic cannabinoids exemplified using cumyl-5F-P7AICA[J]. Drug Test Anal,2020,13(1):74-90. [42] de Souza Anselmo C,Sardela VF,de Sousa VP,et al. Zebrafish (Danio rerio):a valuable tool for predicting the metabolism of xenobiotics in humans[J]? Comp Biochem Physiol C Toxicol Pharmacol,2018,212:34-46. [43] Qi MJ,Shi MZ,Han YL. Application of zebrafish in field of pharmacy[J]. Chin Pharmacol Bull(中国药理学通报),2018,34(7):903-906. [44] Li ZH,Alex D,Siu SO,et al. Combined in vivo imaging and omics approaches reveal metabolism of icaritin and its glycosides in zebrafish larvae[J]. Mol BioSyst,2011,7(7):2128-2138. [45] European Monitoring Centre for Drugs and Drug Addiction. 2010 Annual Report on the State of the Drugs Problem in Europe[EB/OL] https://www.emcdda.europa.eu/publications/annual-report/2010 .[46] Kemp AM,Clark MS,Dobbs T,et al. Top 10 facts You need to know about synthetic cannabinoids:not so nice spice[J]. Am J Med,2016,129(3):240-244.e1. [47] Dresen S,Ferreirós N,Pütz M,et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds[J]. J Mass Spectrom,2010,45(10):1186-1194. [48] Krotulski AJ,Cannaert A,Stove C,et al. The next generation of synthetic cannabinoids:detection,activity,and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA[J]. Drug Test Anal,2021,13(2):427-438. [49] The National Drug Control Office informed the entire category of synthetic cannabinoids flutamide and other 18 new psychoactive substances China became the first country in the world to list the entire category of synthetic cannabinoid substances[J]. Shanghai Chem Ind(上海化工),2021,46(04):70. [50] Sardela VF,Anselmo CS,Nunes I,et al. Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism:progress,outlook,and challenges[J]. Drug Test Anal,2018,10(11/12):1657-1669. [51] Xu DQ,Zhang WF,Li J,et al. Analysis of AMB-FUBINACA biotransformation pathways in human liver microsome and zebrafish systems by liquid chromatography-high resolution mass spectrometry[J]. Front Chem,2019,7:240. [52] Xu DQ,Dai Y,Zhang WF,et al. Rapid identification of MDMB-CHMINACA metabolites using zebrafish and human liver microsomes as the biotransformation system by LC-QE-HF-MS[J]. J Anal Toxicol,2021,44(9):1012-1026. [53] Yue LN,Xiang P,Shen BH,et al. Metabolism of 4F-MDMB-BICA in zebrafish by liquid chromatography-high resolution mass spectrometry[J]. Drug Test Anal,2021,13(6):1223-1229. [54] Yue LN,Yan H,Xiang P,et al. Investigation on metabolites of 5F-MDMB-PICA in zebrafish by liquid chromatography-quadrupe/orbitrap mass spectrometry[J]. J Instrum Anal(分析测试学报),2021,40(5):690-698. [55] Yue LN,Xiang P,Song FY,et al. Metabolism of new psychoactive substances 4F-MDMB-BUTINACA in zebrafish[J]. J Forensic Med(法医学杂志),2021,37(4):493-499. [56] Morales-Noé A,Esteve-Turrillas FA,Armenta S. Metabolism of third generation synthetic cannabinoids using zebrafish larvae[J]. Drug Test Anal,2022,14(4):594-603. [57] Gampfer TM,Wagmann L,Park YM,et al. Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4′-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine[J]. Arch Toxicol,2020,94(6):2009-2025. [58] Kirla KT,Groh KJ,Poetzsch M,et al. Importance of toxicokinetics to assess the utility of zebrafish larvae as model for psychoactive drug screening using Meta-chlorophenylpiperazine (mCPP) as example[J]. Front Pharmacol,2018,9:414. [59] Wagmann L,Frankenfeld F,Park YM,et al. How to study the metabolism of new psychoactive substances for the purpose of toxicological screenings-a follow-up study comparing pooled human liver S9,HepaRG cells,and zebrafish larvae[J]. Front Chem,2020,8:539. [60] Truver MT,Watanabe S,?strand A,et al. 5F-MDMB-PICA metabolite identification and cannabinoid receptor activity[J]. Drug Test Anal,2020,12(1):127-135. [61] Mogler L,Franz F,Wilde M,et al. Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018,EG-2201,and MDMB-CHMCZCA and detection in human urine samples[J]. Drug Test Anal,2018,10(9):1417-1429. [62] Haschimi B,Mogler L,Halter S,et al. Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens[J]. Drug Test Anal,2019,11(9):1377-1386. [63] Richter LHJ,Maurer HH,Meyer MR. Metabolic fate of the new synthetic cannabinoid 7''N-5F-ADB in rat,human,and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry[J]. Drug Test Anal,2019,11(2):305-317. [64] Hei H,Wang JF,Zhang WF,et al. Study of the in vitro and in vivo metabolism of a novel synthetic cannabinoid PX-2 in human liver microsomes and zebrafish[J]. Int J Mass Spectrom,2020,456:116388. [65] Krotulski AJ,Papsun DM,de Martinis BS,et al. N-ethyl pentylone (ephylone) intoxications:quantitative confirmation and metabolite identification in authentic human biological specimens[J]. J Anal Toxicol,2018,42(7):467-475. [66] Cooman T,Hoover B,Sauvé B,et al. The metabolism of valerylfentanyl using human liver microsomes and zebrafish larvae[J]. Drug Test Anal,2022,14(6):1116-1129.
计量
- 文章访问数: 447
- HTML全文浏览量: 5
- PDF下载量: 684